Insilico Medicine plans to push its computer-designed drug into pivotal clinical trials after a phase 2a study demonstrated ...

More than 530 million people worldwide living with diabetes are at risk for developing diabetic retinal disease (DRD), the leading cause of ...

DelveInsight’s, “Interstitial Lung Diseases Pipeline Insight 2024” report provides comprehensive insights about 120+ ...

The $66 million project is part of the company's obligation made to the state after it moved here to invest a total of $120 ...

Spending the day facing the challenges of kidney patients helps workers at a CT pharmaceutical company understand disease and ...

Boehringer Ingelheim has halted development of an obesity drug from Gubra that it originally pledged to advance back in 2017, ...

NEW YORK – Researchers have identified a gene signature that can predict whether early-stage breast cancer patients will respond to neoadjuvant treatment with anti-fibrotic therapies, such as ...

Boehringer Ingelheim, a biopharmaceutical company active in both human and animal health, in partnership with WHO Foundation, today pledged USD 5 million to advance access to quality healthcare ...

Boehringer Ingelheim partners with the WHO Foundation to financially support WHO’s Fourteenth General Programme of Work (2025 to 2028). Credit: PeopleImages.com – Yuri A/Shutterstock. Boehringer ...

INGELHEIM, Germany & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Boehringer Ingelheim and Circle Pharma (Circle) announce a new research collaboration and license agreement with the shared goal ...

Of the four new products it has launched in 12 months, Boehringer Ingelheim (BI) believes Spiolto (tiotropium/olodaterol) and OFEV (nintedanib) have the potential to ...

The US Food and Drug Administration (FDA) has granted approval for Boehringer Ingelheim's SPEVIGO injection to treat generalised pustular psoriasis (GPP). The treatment is indicated for use in adult ...